Medtronic Continues To Deal In Diabetes
This article was originally published in Start Up
Executive Summary
DreaMed, the Israel-based developer of the GlucoSitter glucose control system announced an exclusive worldwide development and license agreement with Medtronic for the development and marketing of the MD-Logical Artificial Pancreas algorithm in Medtronic’s insulin pumps. This is the third Medtronic investment in a diabetes firm made public in the past month.